ABSTRACT
INTRODUCTION

EXPERIMENTAL PROCEDURES
Cell culture and preparation of extracts: P1798 cell culture lineB were established from an ascites tumor population (12) and the clonal isolate P1798-D2 was used in these experiments (13) . Mid log phase cultures (1L, 10 6 cells/ml) were grown in suspension culture and S100 extracts were prepared as previously described (7). S100 extracts were prepared from control cells and from cells treated 24h with 0.1 pM dexamethasone. A single control extract containing 12 mg/ml protein was used throughout these experiments. Extracts from control and hormone-treated cells were not significantly different with respect to protein concentration or RNA polymerase activity (7).
Estimation of the rate of elongation by purified RNA polymerase 1^:
RNA polymerase I was extensively purified from extracts of control and hormone-treated P1798 cells using a procedure described elsewhere (14) .
The specific activity of the purified enzyme was 4.3 and 2.3 nanomoles uridine monophosphate/min/mg protein for control and hormone-treated enzyme, respectively. These differences are within the range of expected variation from one polymerase preparation to another and are not thought to be significant. The specific activity of highly purified P1798 RNA Additional properties of the highly purified polymerase are described elsewhere (14) .
The rate of elongation was estimated by a pulse-chase experiment using a homopolymerically tailed template (15). The template was pR1102 were mixed with an extract from hormone-treated cells. Only fraction C (lane e) was able to reconstitute transcription to a significant degree.
Fraction C contains less than 0.1% of the protein and less than 1% of the RNA polymerase I activity that was present in the S100 preparation from which this fraction was prepared. According to the convention of Mishima et a_l. (17), we designate the transcription factor, present in this fraction, as TFIC.
The ability to reconstitute transcription with TFIC was used to confirm formation of preinitiation complexes in extracts from hormonetreated cells. Such an extract was preincubatd with prMAB/Pvu and TFIC was preincubated with prMAB/Sma. These were mixed and transcription was initiated by the addition of NTPs. As shown in Figure 4 , lane g, only prMAB/Pvu was transcribed. Functional stable complexes did not form with prMAB/Sma during preincubation with TFIC or after mixing with the hormonetreated extract. Therefore transcription of prMAB/Pvu must be due to stable association of this template with factors that are present in extracts from hormone-treated cells.
Template competition experiments were carried out to examine the kinetics of formation of stable complexes in extracts from control and hormone-treated cells. A reaction mixture from control cells was prewarmed to 30°C and stable complex formation was initiated by the addition of prMAB/Pvu. prMAB/Sma was added at intervals thereafter and transcription was initiated with nucleoside triphosphates and allowed to proceed for 15 min. RNA was extracted and resolved on polyacrylamide:
urea gels and the relative amounts of the 292nt and 155nt transcripts were determined by densitometry. As shown in Figure 5A , approximately equal amounts of 292nt and 155nt transcript were formed when both templates were added simultaneously (at 0 sec). Thereafter the relative amount of 155nt transcript decreased as a function of the length of preincubation with prMAB/Pvu. Stable complex formation in control extracts was complete within 1 min as evidenced by the observation that transcription of prMAB/Sma was reduced to less than 5% of that observed from the preincubated template.
A similar approach was used to estimate the rate of formation of This mechanism provides for three different levels of regulation:
(i) a long term regulatory event involving more or less permanent gene activation via stable complex formation; (ii) rapid regulation of the rate of transcription at the level of the factor (TFIC) that is required for initiation; and (iii) regulation of the rate of elongation by RNA polymerase I. We are unaware of any well characterized physiological regulatory event that involves stable complex factors although this possibility has not been carefully researched. Species specific transcription of rDNA is apparently attributable to stable complex factors (10) and nucleolar dominance in somatic hybrids may involve loss or suppression of genes encoding stable complex factors (19) . Regulation at the level of initiation is well documented by the data presented in this paper as well as other data from our laboratory (7) . Such a mechanism accounts for the effects of glucocorticoids upon rRNA synthesis in P1798 cells and recent data from our laboratory indicate that initiation factor TFIC is involved in inhibition of rRNA synthesis in cells treated with inhibitors of protein synthesis (20) . We suspect that this may be a common mechanism for regulation of the rate of synthesis of rRNA by substances that influence that rate of cell proliferation. Regulation of the rate of elongation by RNA polynerase I is controversial and has been invoked to account for increased activity of RNA polymerase I in transformed cells (21) .
However, we have not observed differences in the rate of elongation by purified or partially purified polymerase from liver and hepatoma (14) .
We concur that this is a potentially significant regulatory site but submit that physiological regulation at this level remains to be demonstrated.
